CRP, C-Peptide, and Risk of First-Time Cardiovascular Events and Mortality in Early Type 2 Diabetes: A Danish Cohort Study
Authors' conclusion
The finding of high hs-CRP as a stronger prognostic biomarker of all-cause mortality than of CVEs may facilitate improved early detection and prevention of deadly diseases besides CVEs. Conversely, elevated C-peptide as a strong CVE biomarker supports the need to target hyperinsulinemia/insulin resistance in T2D CVE prevention.
Study context
- Population
- Patients with recent-onset T2D; CVE analysis in those with no prior CVE; hs-CRP measured in 7,301, C-peptide in 5,7655,765 with C-peptide · CVE analysis in those with no prior CVE 6,407
- Participants
- 7,301 patients
- Exposure
- High vs low hs-CRP, alone or combined with C-peptide
- Outcome
- First CVE (MI, stroke, coronary revascularization or CV death) and all-cause mortality
- Follow-up
- Median 4.8 years
Methodological detailsDanish Centre for Strategic Research in Type 2 Diabetes cohort, Cox regression with adjusted HRs, interaction test between hs-CRP and C-peptide
- Danish Centre for Strategic Research in Type 2 Diabetes cohort
- Cox regression with adjusted HRs
- Interaction test between hs-CRP and C-peptide
Main finding
As reported in the abstract
median 4.8 years
Each group vs low hs-CRPEstimate (95% CI)
High hs-CRP
aHR (CVE) 1.45(1.07–1.96)
High hs-CRP
aHR (all-cause mortality) 2.47(1.88–3.25)
Observational data: associations, not effects.
Further findings
| Outcome | Estimate | |
|---|---|---|
| CVE and all-cause mortality by combined hs-CRP and C-peptide · median 4.8 yearsHigh hs-CRP + high C-peptidevs Low hs-CRP + low C-peptideHighest risk | aHR (CVE) 1.61 (CI 1.10–2.34) | |
| CVE and all-cause mortality by combined hs-CRP and C-peptide · median 4.8 yearsHigh hs-CRP + high C-peptidevs Low hs-CRP + low C-peptideHighest risk | aHR (all-cause mortality) 2.36 (CI 1.73–3.21) | |
| 0.20.5125Ratio (log scale) |
CVE and all-cause mortality by combined hs-CRP and C-peptide · median 4.8 years
- Among high C-peptide, CVE risk did not differ by low or high hs-CRP, whereas all-cause mortality risk did
Original publication
CRP, C-Peptide, and Risk of First-Time Cardiovascular Events and Mortality in Early Type 2 Diabetes: A Danish Cohort Study. Diabetes Care. Published 17 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →